expect leav littl scope upsid neutral
price perfect execut initi neutral
believ siemen healthin deliv core manag target set
ipo alreadi price current level investor assumpt
stabl high qualiti imag segment sale continu take
share diagnost sale stem market share loss leav
littl room execut shortfal increas competit intens neutral
upsid risk cost save target imag key downsid risk
see one key upsid downsid risk respect key upsid risk see
cost reduct target may prove conserv key downsid risk
see evidenc recent ub evid lab idn survey challeng
consensu imag assumpt growth market idn
execut said like buy siemen futur lowest score
big three provid whilst execut survey saw healthin
clear innov leader joint highest score score poorli after-sal
servic contrari heard in-person radiologist interview
treat data cautious hope monitor develop close
diagnost turnaround key uncertainti lead indic look good
diagnost divis turnaround depend success new atellica
instrument detail side-by-sid analysi suggest machin compar
market leader roch current product coba whilst analysi give us
confid turnaround abbott launch alinti believ roch
like refresh portfolio next coupl year increas competit
uncertainti see segment grow line market growth
valuat ep premium multipl low-growth busi
dcf-deriv wacc pt equival ubs pe
ev/ebitda low risk year pat adj compound-annual-growth-rate whilst valuat
comparison complic prefer philip within med-tech space
ep adj higher risk year pat adj compound-annual-growth-rate sotp basi
pt equival imag segment pe diagnost
trade data key metric
compani account thomson reuter ub estim metric mark ub analyst adjust appli valuat base averag share price year base
share price apr bst
report prepar ub limit analyst certif requir disclosur begin page
ub seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
 launch atellica allow diagnost stem market share loss
 healthin imag advanc therapi segment grow
market
 healthin deliv overhead cost reduct
market growth driven softwar china
radiologist see healthin innov leader
growth margin cash profil remain stabl
market growth driver
sticki market near-term uncertainti
financi revenu growth improv
balanc sheet cash flow
ub research thesi map guid think report
 launch atellica allow diagnost stem market share loss
ye see healthin grow line market growth gradual
improv growth rate believ new product atellica par
market leader roch see risk new competitor product launch next two year
 healthin imag advanc therapi segment grow market
above-market growth imag advanc therapi line believ imag deliv
organ sale growth vs market driven healthin percept leader
innov though percept inferior after-sal servic risk assumpt see
advanc therapi busi deliv market growth
 healthin deliv overhead cost reduct end
ye line manag guidanc model full major
save appear imag busi
believ siemen healthin deliv core manag target set ipo
alreadi price model cost save drop profit
expert call ub evid lab survey suggest healthin seen innov leader
imag allow take share diagnost recent product launch bring
healthin line competit stem market share loss howev believ
current valuat alreadi price improv fulli
detail analysi new product atellica diagnost test menu hardwar specif rel
key competitor healthin previou platform channel check lab manag radiologist
hospit procur manag ub evid lab survey idn execut
view current valuat assum continu imag market share gain overhead
cost reduct success yet gradual turnaround diagnost segment
assumpt leav littl room execut medium-term guidanc
upsid downsid
siemen healthin design manufactur distribut medic devic global compani
split three segment imag sale advanc therapi
 launch atellica allow diagnost
stem market share loss
ye see market growth gradual improv
growth rate believ new product atellica
par market leader roch see risk new competitor
product launch next two year
technic specif healthin atellica roch coba
broadli similar atellica offer test us broadli similar coba
whilst atellica run immunoassay test per hour per sq
ft chemistri throughput lower coba claim hour
autonom oper time vs atellica convers expert
suggest abbott roch may process refresh
success launch atellica growth gradual increas
medium term pick-up margin middl manag
guid rang
figur atellica stem share loss view
ub estim market growth
figur drive margin expans
figur atellica test menu competit broad across deep within categori
drug abuse/toxicolog
ub analysi compani materi
 healthin imag advanc
therapi segment grow market
above-market growth imag advanc therapi line believ
imag deliv organ growth vs market driven
healthin percept leader innov though percept
inferior after-sal servic risk assumpt see advanc
therapi busi deliv market growth
in-person interview radiologist gener support healthin
howev idn execut ub evid lab survey said
like buy siemen next lowest score big
three provid whilst siemen seen innov leader score
poorli after-sal servic metric
believ investor believ imag busi continu take
market share medium term
figur loyalti healthin low
figur after-sal servic appear gap
siemen show largest
differ current
question ask vendor respond current use
manufactur like use within next year three respons
allow
question ask manufactur deliv best attribut
 healthin deliv overhead
cost reduct end
ye line manag guidanc model full
major save appear imag busi
limit though osram gamesa two compani spun siemen
ag deliv greater expect cost reduct product gain
base investor discuss appear broadli consensu
central invest case investor view
believ investor
price base case
assumpt line
current valuat impli execut mid-term guidanc
discuss investor healthin current valuat suggest
investor expect manag success execut core
manag target set ipo see outcom
like scenario also reflect estim
imag stabil believ investor expect healthin continu slowli
take share imag busi given histor track record
estim growth market grow like consensu
overhead cost reduct investor spoke line
conserv compani guidanc cost save howev
investor spoke saw conserv see potenti signific
diagnost turnaround investor spoke anticip success albeit
gradual turnaround diagnost segment although investor
bearish given new product launch competitor abbott
dcf-deriv pt broadli line current valuat
assum manag deliv midpoint medium-term guidanc
sale
sale
sale
portion cf
back dcf analysi segment sotp analysi assum
healthin imag advanc therapi divis trade pe
ev/ ebitda diagnost pe ev/ ebitda
multipl appear full sector peer reinforc view
market alreadi price high likelihood cost save imag market share
gain turnaround diagnost segment
imag
figur ub base-cas scenario appear price investor
upsid downsid
trade
april
upsid imag advanc therapi segment grow
ahead market manag deliv cost save
guidanc also assum atellica perceiv
superior competitor platform drive faster-than-expect improv
growth margin
base imag segment continu grow market whilst
advanc therapi segment grow line market assum
manag deliv guid overhead cost reduct
drive margin imag advanc therapi busi
middl long-term guidanc rang also assum atellica success
stem healthin market share loss cost-out leverag drive
margin improv group level
downsid imag segment grow market
competit intens increas result neg oper leverag
less cost save reach oper profit line diagnost
competitor launch outshin atellica healthin continu lose share
margin remain depress
distribut medic devic global compani split
three segment imag sale advanc
therapi sale diagnost sale
compani headquart erlangen germani
siemen ag remain major sharehold
revenu region
healthin leader diagnost
intervent imag market expect
continu grow go forward mainli driven
volum growth emerg market healthin
lose share in-vitro diagnost
market estim grow
platform manag expect drive return
market growth medium term reimburs
chang us key market could result market
revenu segment
exhibit siemen healthin
healthin chart
sale
imag equip robot use
therapi robot c-arm
sale
clinic lab point care test
equip reagent
figur healthin histor abl take
market share imag
figur healthin lost share diagnost sinc
launch dimens
sale
mri ct ultrasound x-ray molecular
figur margin imag ahead
peer
figur dimens test menu narrow
figur atellica autom par peer
figur imag attract cash profil
ub summari product guid http //www captodayonlin com
copyright colleg american pathologist use permiss ub
figur imag somewhat cyclic market
philip healthcar note cer refer constant currenc
figur us diagnost reimburs come
pressur result regulatori chang
figur recent order growth strong despit
concern us healthcar reform
note total healthcar order fiscal calendar year
figur target net debt/ebitda
target ebitda
equival
siemen healthin design manufactur distribut imag lab
test equip compani market leader major busi
line view sit behind signific protect barrier entri
believ industri defens predict outlook
imag largest three manufactur includ healthin account
ub estim growth market competit dynam
appear stabl healthin estim grown averag
past year driven reput innov among custom
see market growth rate futur
diagnost healthin one larg four high-volum laboratori test
provid ub estim market focus high-volum
lab newly-launch analyz atellica plan return divis
market growth deliv recent year expect
see signific improv revenu growth
figur healthin
diagnost imag equip mri ct x-ray
appli x-ray scanner use surgeon
procedur
test includ vitamin lsd run analyz place
multipl comparison complic direct peer divis
pure-play competitor believ healthin like compar
philip frequent believ use comparison limit
sinc two-third philip ebita adj compet healthin
believ sum-of-the-part sotp multiple-bas analysi like
use
imag believ radiat oncolog provid elekta varian
medic provid best comparison sinc although differ
industri econom technolog similar howev
elekta varian signific technolog project develop
diagnost examin specialist provid includ biomerieux
well life scienc provid thermo fisher agil
overhead expect debat whether conglomer discount
appropri proport anticip overhead save
split siemen ag fall profit line
figur third philip
ebita adj relev
philip ub estim note sum
due unalloc overhead image-
guid therapi equival advanc therapi
ub bloomberg
includ elekta varian medic includ sysmex diasorin biomerieux includ thermo fisher agil
healthin seen innov leader imag
pivot question healthin imag divis grow market
growth
ub view ye believ divis deliv organ growth
medium term driven siemen brand percept leader innov
evid channel check radiologist analysi histor region
reimburs market growth trend healthin track record deliv
past year estim imag advanc therapi
combin grew year market grow believ
continu outgrow market model organ growth futur
healthin believ innov advantag peer
channel check radiologist broadli confirm
softwar along competitor healthin invest heavili imag
recognit softwar artifici intellig ai order save
radiologist time come mundan task manipul rib
make fractur easili visibl
high low end healthin first launch mri magnet
use ultra-high-end hospit recent launch somatom go valu
manag argu focu innov also allow healthin
produc machin lower unit cost peer
oper margin higher competitor ge healthin plan
lift margin medium term model midpoint
rang expans driven mainli overhead cost reduct
stabl market despit headlin risk custom consolid
healthin ge philip togeth account market
see protect barrier entri technolog brand low-
price competitor tri break market past
success
innov
see sever hypothet risk market though view
potenti seriou near term
afford act reform survey us hospit execut
suggest caution obamacar reform also suggest imag
target cost save industri order strong recent
cyclic competitor philip saw revenu growth suggest
industri cyclic
reimburs reform penetr rate us twice
seen oecd countri believ larg due financi
incent face hospit may chang part long-term reform
anticip custom consolid like continu drive annual
atellica may central debat
pivot question launch atellica allow healthin stem market
share loss
ub view ye although expect healthin outgrow market
time-frame believ atellica correct issu found previou
platform market highli sticki
evid detail comparison test menu hardwar specif versu
mainstream peer well channel check lab manag
diagnost group sale nevertheless believ
debat centr divis previou gener product dimens
driven organ revenu growth sinc market grow
estim manag hope new product atellica launch
stem market share loss
believ assumpt realist
test menu conduct detail side-by-sid comparison test menu
major competitor suggest dimens materi behind
peer atellica broadli line
hardwar summari cap today technic like-for-lik comparison
hardwar differ manufactur suggest dimens chemistri system
lag peer atellica market literatur suggest fix
howev believ custom highli sticki anticip
major improv revenu growth rate
sticki custom recur revenu stream weak cash flow
see diagnost test industri fundament attract
razor-razorblad
healthin sell hardwar discount list price return
guarante volum high-margin test subsequ year yield
predict revenu stream durat averag five- seven-year
high barrier entri see small risk new entrant space
pathologist need trust test equip provid deliv stabl
reagent cours contract switch cost high
substanti intellectu properti ip test menu anazyz
flow industri weak howev given machin placement cost
see near-term uncertainti us market due new regul
protect access medicar act pama provid substanti declin
govern reimburs healthin custom howev major
impact seen test provid revenu growth rate yet
siemen healthin global medic engin compani focus
design manufactur distribut imag clinic lab equip
relat softwar servic report purpos group split
imag busi includ mri ct ultrasound x-ray molecular pet
system healthin global leader overal market
see grow year leadership posit mri ct
submarket market oligopolist healthin ge philip account
global sale combin key barrier entri around
technolog expertis brand view
healthin split three
segment report purpos
advanc therapi unit compris manufactur sale
procedur major devic use angio lab includ c-arm
x-ray imag industri dynam similar seen imag
imag equip use minim
diagnost segment sell test equip reagent use clinic
test laboratori healthin focus high-volum end
market top-four player alongsid roch abbott
combin account market sale structur along razor-
razorblad model ensur predict stabil sale typic
see signific technolog revenu synergi imag
advanc therapi healthin believ also signific synergi
diagnost rest busi
sale
imag equip robot use
therapi robot c-arm
sale
clinic lab point care test
equip reagent
top four player oligopoli
sale
mri ct ultrasound x-ray
accord healthin top manufactur account global
market howev definit equip order exclud ultrasound
stabl market growth structur driver
believ healthin oper market continu grow
per year medium term includ price pressur
healthcar cost inflat age popul increas preval
obes lifestyle-associ disord improv access
healthcar especi emerg market drive annual healthcar cost
inflat estim
figur grow rate obes
un depart econom social affair
cdc nutrit examin survey
imag market see volum growth per year
estim driven larg emerg market includ china
focus build physic healthcar capac price pressur
accord estim off-set invest softwar develop
market focus build interpret capac drive
effici efficaci improv
diagnost estim annual market growth includ least
annual price pressur see gener shift develop
emerg market toward diagnost prophylact away
cur treatment healthcar spend benefit test manufactur
consolid reimburs cut drive price pressur
typic medic devic compani believ healthin face price
pressur particular due custom consolid rate hospit
clinic lab system consolid increas recent year driven cost
pressur put overcapac anticip trend continu
figur hospit consolid
hospit
belong health system
figur clinic lab
note poc refer point care test
also see potenti short- long-term market uncertainti
clinic reimburs protect access medicar act
pama came effect januari reduc laboratori
reimburs us lab may tri pass pressur
supplier includ healthin longer term believ pama could
acceler process consolid among healthin custom neither
healthin competitor seen signific impact
busi far
reimburs reform key
long-term imag headwind reimburs level us
stabilis past year period signific cut howev
see risk long term value-bas care could drive us
penetr rate incent chang
figur lab face cut medicar reimburs
figur us imag penetr high
note hcpc code respect
instal base key drive recur revenu
half healthin revenu recur base servic reagent
consum suppli contract suffici instal base place growth
stabl predict
recur revenu stream
major busi
imag advanc therapi develop market estim
servic softwar sale account sale larg part
manufactur market messag dedic highlight benefit
softwar accompani hardwar especi around automat
imag recognit label capabl contract typic last year
believ
lab consum reagent sale consum servic account
diagnost revenu devic sold loss leader given
custom free return year reagent volum commit
life contract custom frequent option upgrad
instrument extend life reagent contract
see oligopoli stabl
barrier entri support oligopoli
sub-seg substanti oligopolist natur healthin
market leader imag among top five clinic diagnost
barrier entri view take form technolog brand switch
technolog custom initi cost purchas minor
total cost ownership new entrant would need develop highli reliabl
devic could manufactur low cost order take share
addit within imag accompani softwar would hard
replic within diagnost signific time would requir gain
regulatori approv test view
brand purchas manag appear will pay price premium
reassur come high-qual brand within imag key
concern machin break within diagnost
reagent stabil ensur consist predict result time
switch cost radiologist spoken suggest technician
retrain cost purchas consider switch vendor
effort standardis equip across system howev
believ barrier entri import clinic diagnost
accord healthin revenu recur servic softwar contract
believ develop market greater skew toward type revenu
averag suppli contract length year valid process
new machin last month
figur barrier entri support stabl oligopoli
ub note market share estim base equip servic sale
see diagnost imag lab equip market defens
capit equip market though cyclic visibl especi
cyclic see relat payer mix rather volum privat
payment rate materi higher govern rate unemploy
level fall payer mix worsen predominantli us emerg market
phenomenon sinc europ larg major healthcar paid via social
secur directli govern
addit also see cyclic volum like imag sinc
estim larger proport end-pati undergo elect
ivd
figur small exposur econom cycl
figur though region nuanc exist
synergi limit imag
key segment synergi see imag
advanc therapi segment imag core
see synergi
imag clinic diagnost
technolog imag advanc therapi use imag hardwar
softwar core albeit differ set therefor believ
innov within one segment appli also believ
healthin strong brand percept innov transfer across
access c-suit capital-expenditure budget increasingli decid c-suit
level within hospit offer give healthin place
negoti tabl provid compani cross-sel opportun
healthin believ access c-suit synergi appli clinic
diagnost rest group channel check could confirm
major decision-mak factor sinc purchas decis typic
taken differ level
demand cyclic demand healthin product somewhat cyclic
whilst believ healthcar less suscept downturn
capit equip industri seen neg impact growth
earn previou econom cycl especi imag
price continu expect healthin face price pressur
per year driven custom consolid reimburs cut
govern global greater pressur limit healthcar cost
inflat could advers impact industri
regulatori volum price shift global regul could advers
impact volum growth price exampl us repeal replac
healthcar debat could neg impact us patient volum global shift
toward value-bas care could lower demand medic devic
protect access medicar act pama could neg impact price
regulatori qualiti control safeti medic devic industri
increas scrutini regul includ fda european
japanes chines health author number manufactur qualiti
inspect increas significantli recent year regulatori
requir becom stringent
withdraw product shutdown manufactur facil furthermor
use healthin product may result advers effect patient
diagnost turnaround believ turnaround diagnost busi
core compon healthin stori turnaround highli
depend success flagship atellica instrument launch
remain earli stage
custom consolid healthin custom imag
diagnost segment consolid acceler rate particularli
us could drive greater price pressur healthin
minor sharehold siemen ag set remain control
sharehold siemen healthin ag state intent maintain
ownership medium term
innov healthin unabl keep pace innov
busi segment demand healthin tradit offer may suffer
foreign exchang healthin expos currenc move excess cost
eur excess revenu usd compani implement fx hedg
strategi wherebi net exposur hedg division level
see siemen healthin imag segment well posit expect
busi sustain deliv growth margin slightli ahead peer
near medium term
pivot question healthin imag segment grow
market growth
ub view ye believ segment deliv organ growth
medium term driven healthin brand percept leader
evid channel check radiologist analysi histor region
reimburs market growth trend healthin track record deliv
market growth expect global diagnost imag market continu
grow valu term us reimburs level stabil
recent year order strong despit concern healthcar reform
emerg market growth acceler follow period weak
particularli china global price pressur appear
off-set softwar enhanc
market share healthin wide perceiv innov leader base
channel check given compani strong track record market share
gain recent innov product launch expect healthin
continu grow slightli ahead market howev given turnaround
seen philip recent out-performance like slight view
margin cash healthin highest margin big three
diagnost imag player cash need rel low expect
dynam continu margin expans driven cost reduct
figur imag
market growth stabl
figur ub estim imag growth
figur ub estim imag margin
ub estim market growth
healthin design manufactur wholesal imag test equip
mri molecular imag ct ultrasound well accompani
softwar servic support
figur imag advanc therapi swot analysi
integr smart softwar
innov shift toward
ambulatori er use
market leader stabl oligopolist
above-market growth industry-
perceiv innov leader
market growth
medic devic subsector driven
compar patient
cyclic healthcar
us healthcar reform could result
provid incent drive lower
particularli us
figur imag advanc therapi porter five forc
threat substitut product
launch
bargain power supplier
intens industri rivalri
bargain power custom
domin three-play oligopoli
product offer materi
high relianc singl payer
govern region
threat new entrant
abil build high-tech machin
low unit cost
brand consist reliabl
after-sal servic hard replic
market growth driven softwar china
believ develop market like deliv stabl inflationari growth
volum growth come emerg market especi china
accord healthin global market worth grow
per year estim volum growth price pressur
larg off-set increas focu sell integr softwar
near term see risk chang dynam us reimburs
stabl sinc gener trend custom consolid continu
account act repeal replac uncertainti
translat fewer order
long term howev see risk transit value-bas care
payment model us could result materi market contract
within china see expans privat market suffici drive
double-digit local market growth although believ growth seen prior
end
figur total market grow
ct mri x-ray ultrasound pet imag techniqu use investig
bodi diagnos diseas without intrus
ultrasound use high frequenc sound wave similar way hunt bat
significantli cheaper imag modal
irradi patient unlik x-ray scan
figur healthin sale split modal
figur technolog vari price
comput tomographi ct machin combin number x-ray imag
build model bodi wide use emerg room sinc
despit offer lower qualiti soft tissu imag mri scan much
quicker often less five minut
magnet reson imag mri machin use magnet field radio
wave gener high-qual soft tissu imag mri machin typic
expens ct machin scan take longer
expos patient harm radiat
market appear stabl near medium term
see global imag diagnost capit equip market larg stabl
near medium term
us reimburs stabil period volatil
us repeal replac uncertainti translat weak order
believ unlik hospit execut focu make save
custom consolid continu especi us also elsewher
concern market volum growth could reduc effort
reduc time patient spend machin scan patient
throughput per machin increas less concern outsid mri
patient typic spend littl time actual machin time spent
room get patient settl readi scan hard see
time could reduc materi
exposur econom cycl higher clinic diagnost
see imag diagnost defens capit equip
busi though cyclic visibl willing patient pay
care highli inelast albeit healthcar spend especi us
extent depend patient abil pay
reimburs volum
custom consolid
littl room reduc patient in-
room time
howev headlin growth rate may mask underli cyclic somewhat
us market declin recess larg off-set government-l
invest china consist parti strategi invest respons
global econom weak counter-cycl behaviour unlik
repeat view
figur market growth larg stabl
past decad
figur weak philip us growth off-set one-off
 healthin show america
us reimburs stabil period volatil
us reimburs trend appear stabil past coupl year
though healthin custom seen success reimburs cut
healthin us custom reimburs govern via medicar
medicaid privat insur compani test conduct patient
one two mechan
per unit almost outpati procedur includ conduct
hospit set test reimburs singl fix price hospit may
abl make profit test
bundl rate inpati procedur reimburs given part
wider reimburs code known diagnosis-rel group drg
design cover entir treatment
reimburs rate defin year prior treatment
start make signific cut reimburs rate
imag taken outpati respons alleg
centr self-ref patient take advantag extra reimburs
even though medic rational test may limit outpati
test conduct larg unaffect
reimburs physician fee schedul
reimburs hospit outpati prospect payment diagnost test
inpati would mostli reimburs part within larger bundl
figur outpati centr saw signific cut
sinc stabilis
figur inpati centr hospit seen
ub estim base ferrari et al cardiovascular imag payment
reimburs system jacc cardiovascular imag volum issu
ub estim base ferrari et al cardiovascular imag payment
reimburs system jacc cardiovascular imag volum issu
sinc reimburs outpati clinic hospit
larg stabl view overal increas
us healthcar reform near-term headwind hospit budget
believ concern market repeal account
act also known obamacar similar near-term us
healthcar reform could neg impact demand healthin imag
capital-expenditure relax
survey hospit execut suggest expect hospit budget
inde worsen result repeal replac debat
limit tangibl impact us
healthcar reform far
figur hospit execut optim fade
figur partli driven repeal replac debat
decreas significantli
decreas somewhat
increas somewhat
increas significantli
ub evid lab ub ask us hospit execut
expect overal capit spend chang state period
ub evid lab ub ask us hospit execut
budget expect chang sinc elect result cours
repeal replac debat trend line show diffus
respond expect better respond expect wors
whether outpati part test reimburs hopp
howev see sever reason posit headlin survey
strong order growth three larg imag player post
order growth ahead expect despit market commentari around
increas scrutini hospit decision-mak view suggest fewer
healthcar institut delay purchas decis therefor
revenu growth strong
imag high prioriti accord survey hospit execut
rank imag one least like sourc cost save case
figur recent order growth healthi
respons slowdown capit spend
note total healthcar order fiscal calendar year
product area
ub evid lab ub ask us hospit execut
categori spend like cut case potenti paus
slowdown capit spend
impact overst implement result
neglig increas order suggest limit impact even event
complet repeal view
figur radiolog market clear beneficiari
figur unlik space like orthopaed
impact visibl
orthopaed
impact
visibl less
custom continu consolid reduc redund capac
rate hospit system consolid increas sinc believ
driver behind system consolid desir reduc total capac
includ imag capit equip
figur number us hospit belong chain
figur us hospit increas recent year
hospit
belong health system
number deal
number hospit involv
easili visibl us given hospit market privat
believ similar trend also visibl europ emerg market
privat hospit provid freseniu helio capio mediclin
expand via recent year includ signific cross-
govern provid increasingli centralis purchas order
take advantag scale china uk two exampl
frequent hear becom effici past year
capac reduct evid
europ emerg market
well us
figur freseniu helio sale major acquisit
rhk quiron mark
figur provid like capio consolid
expect consolid continu drive price pressur line
us one highli penetr develop market world
twice mani ct three time mani mri scanner per capita versu
figur us twice median oecd ct
figur three time mani mri scanner
believ high level penetr larg due current
reimburs structur provid financi incent encourag
physician order mani scan believ could possibl help patient
fee-for-servic ff domin current global reimburs model
reimburs care provid base volum cost care provid
higher volum higher cost care provid higher
reimburs receiv theoret provid financi incent
over-test higher unit cost clinic necessari order maximis
see mis-align incent especi pronounc us
roll-out altern value-bas payment model key risk us
capit equip demand view value-bas system would turn
radiolog depart hospit revenu driver test given
attract addit reimburs cost centr scan incur cost
increment reimburs
us govern slowli chang way pay healthcar broad
implic across healthcar univers
order elimin econom incent over-treat patient govern
undertak large-scal trial wherebi give budget provid
episod care hip replac treat patient
period time per dialysi patient per year regardless
servic provid give cost incur provid treat patient
less budget provid keep major save
value-bas care
trial suggest diagnost test sourc cost save care provid
though opportun outpati rehabilit centr larger
shift could neg impact capit equip demand time drive
us penetr rate toward seen develop countri
drive penetr
large-scal shift unlik next three five year
howev see large-scal shift unlik within next three five year
given republican administr appear place lower prioriti
expans value-bas care previou democrat administr
speed roll-out value-bas care trial slow materi sinc
longer term still expect value-bas care reimburs programm
roll
disrupt depart human servic hh seen
senior staff turnov may slow process
roll-out value-bas care
slower
advanc may signal renew focu value-bas care
suggest shift on-going
momentum remain act care provid financi
incentivis paid value-bas care programm januari
may prove suffici drive switch
bundl payment improv
medicar access chip reauthor act
china appear stabl period weak
china second-largest countri sale siemen healthin see
growth sustain near medium term
follow period strong double-digit market growth market slow
low single-digit rate view slowdown driven shift
govern focu parti focu roll univers
coverag citizen includ large-scal construct tier
univers hospit shift expand lower-ti centr
especi rural set necessarili need high-grad
figur driver chines healthcar expans chang
note sum due round
roll-out govern social
expenditur grow
pocket growth
howev compon parti healthcar strategi encourag
expans privat healthcar sector therefor expect
chines market return previou growth rate
believ on-going expans privat market could help drive increas
demand expens intern equip suggest growth
rate sustain
figur chines recov sinc
tier hospit roughli analog scale prestig univers hospit
west although defin associ research institut
radiologist see healthin innov leader
healthin largest three oligopolist market leader market
see high stabl barrier entri healthin track
record take share deliv higher margin peer divid
segment three subseg
larg capital-expenditure includ mr ct molecular x-ray devic
discuss radiologist healthin consist flag
leader innov believ leadership translat histor
growth line ahead market also expect healthin
maintain industry-lead margin howev think rate market
ultrasound healthin histor under-perform ultrasound
subseg manag strategi improv trajectori
though believ could struggl take share medium term given
healthin materi stand-alone popul health
busi make signific invest develop one see
posit given competitor programm met limit success
larg capital-expenditure histori strong execut
see strong barrier entri imag market limit scope new
low-cost entrant make signific headway industri near
technolog whilst radiologist spoken agre
littl technolog product differenti imag manufactur
nevertheless believ technolog hard mimic similar price
healthin develop abil build reliabl machin cost-
effici price expertis may hard copi
brand count even technolog copi brand
purchas price minor portion total cost ownership
opportun cost downtim sometim cite import
consider buy big three purchas manag get
comfort total cost ownership predict
ultrasound seen upsid
opportun
figur imag concentr
ub estim base equip
servic sale includ ultrasound
servic requir low-cost competitor offer equip box
unlik gain traction provid necessari aftercar
barrier entri revolv around
technolog brand servic
time machin servic
strong track record market share gain
healthin imag busi deliv revenu compound-annual-growth-rate past
decad take share market grow year channel check
suggest share gain larg driven radiologist percept
healthin innov leader within space
larg capital-expenditure strength driven innov brand
channel check suggest radiologist see healthin innov
leader larg imag capit equip particularli ct scanner
compani seek build brand percept seri recent
ultra-high-field mri healthin first compani receiv eu us
approv clinic mri machin whilst devic usabl clinic
set believ target toward research centr especi
investig use neurolog
somatom go valu ct platform allow remot control
ct scan process use tablet allow technician spend time
patient
believ either innov major chang
industri help maintain percept healthin offer
margin superior product competit price custom
figur imag deliv
revenu compound-annual-growth-rate
sale imag
recent launch built
percept healthin
along philip ge healthin spend signific resourc
develop system accompani hardwar offer believ
system enabl off-set price pressur core hardwar system
particularli softwar
advanc
integr ai
artifici intellig ai ai reduc amount time radiologist spend
segment aorta measur heart size calcul believ
softwar could expand aid clinic decision-mak process time
figur healthin build ai imag databas
refer tesla strength magnet use part imag within clinic
set current standard care although mri also exist higher magnet
strength allow higher imag resolut
cinemat volume-rend techniqu cvrt allow photo-
realist imag produc human bodi technolog give
physician abil add remov imag layer tissu clearer
visualis ahead procedur
figur rib virtual splay visualis break
figur visualis techniqu enhanc
siemen healthin note comparison tradit volumetr
render techniqu vrt left cinemat cvrt right
clear us whether healthin softwar offer area
superior peer
philip recoveri sinc cleveland issu
least part histor growth out-performance healthin rel
market past decad due under-perform philip though
believ direct impact small
philip issu minor driver
healthin out-performance
view
philip shut cleveland ohio ct manufactur plant
inspect exclud philip us ct market around
year work shift product facil least
custom like bought altern supplier healthin
estim healthin deliv organ sale compound-annual-growth-rate imag
advanc therapi combin healthin
estim market growth estim philip equival sale
compound-annual-growth-rate given limit disclosur hard quantifi
drug administr fda respons among mani thing
ensur good manufactur process medic space
imag busi stage includ deliv sale
sale imag combin major divest
meantim awar sale busi
sale assum sale busi assum
mobil c-arm sale reclassifi workflow solut
philip imag custom servic busi combin gener sale
 divis estim sale acquir
busi includ volcano spectranet philip direct
competitor healthin imag divis
healthin report organ sale growth segment fy fy
addit disclosur avail group level
import philip issu drive out-performance though
estim could account compound-annual-growth-rate
figur philip market share donor
weak due
philip recov sinc
still visibl
year past year
deconsolid
ub note chart includ area healthin sinc
exit includ hear aid radiat oncolog like lower
identifi five fda warn letter receiv healthin
five close materi better philip par ge
suggest qualiti control effort risk healthin
figur qualiti control line better peer
data avail fda databas regard warn letter prior
philip deliv organ growth equival under-perform
versu normal market growth assum ge healthin split lost sale
healthin histor under-perform ultrasound posit
number player market share accord manag
howev ultrasound key driver futur growth whilst see ultrasound
attract market within diagnost imag healthin
ramp invest believ compani may struggl
take signific share medium term given increas competit intens
philip believ philip market leader ultrasound particular
domin cardiolog set philip ambit take share
cardiolog
imag
expand
gener
ultrasound market key
growth opportun
healthin accord
competit intens
appear rise
ge continu take share ultrasound claim grown twice
fast market ambit continu
grow high-single-/low-double-digit rang
low-cost competitor ultrasound market fragment ct
mri greater presenc low-cost competitor mindray
believ fragment possibl part owe lower servic requir
figur ge ambit grow twice fast
market doubl ultrasound busi
figur low-cost competitor mindray shown
mindray note mindray taken privat longer
howev market growth still support believ growth ultrasound
year wider imag space order revenu growth
improv recent year driven increas penetr ultrasound
emerg ambulatori set
accord compani healthin increas spend within ultrasound
larg absent healthcar it/consult busi
offer consult servic hospit health system
form popul health manag financi manag health
informat healthin divest similar healthcar compani
healthin heavili
involv healthcar see
indic capit
whilst believ in-hous capabl may give healthin competitor
advantag time particularli reimburs model shift toward value-bas
care believ healthin strategi sound
philip track record believ consensu view philip
effect fail gener econom profit busi despit sever
year invest one main debat philip surround disciplin
 capit alloc particular focu health
compet think healthin core compet engin
whilst automat imag recognit softwar clear overlap core
compet think popul health manag
softwar applic clear overlap given larg number non-
healthcar softwar compani includ googl seek enter
field believ competit intens like sever
partnership approach healthin offer similar servic seri
partnership compani focus area leverag expertis
healthin effect suppli data third parti
believ capital-effici approach long-term opportun
taken peer
growth margin cash profil remain stabl
sinc expect near- medium-term industri dynam chang
materi believ imag segment histor five-year financi profil
reason guid futur
past perform may
reason guid
futur
growth anticip revenu growth slightli market growth
margin see profit margin expand driven overhead cost
reduct midpoint manag mid-term guidanc
flow think cash-flow profil remain attract given low capital-expenditure
sale growth trajectori margin level continu
estim healthin outgrown imag market
past year whilst believ continu outgrow
market given channel check suggest reput innov
cautious assum growth given on-going improv philip
major market-shar donor previou year
expect season persist line player healthcar
capital-expenditure space skew toward sale profit deliveri
ub estim market growth
note imag segment shown view broadli analog
current disclos imag advanc therapi segment
also believ healthin continu deliv strong profit margin
low driven mainli overhead cost reduct
figur healthin high imag margin rel
peer
figur see margin expans driven overhead
 use issuer adjust ebit metric closest equival
chart even though may directli compar
imag segment gener strong cash flow believ attribut
low capital-expenditure requir manufactur process low capit intens
reli heavili semi-skil skill labour rather mechanis
capex/sal ratio line peer
figur convers strong
figur lead low imag capital-expenditure requir
ub photo healthin facil
compani report note includ consum busi
figur mr ct imag peer summari
jutif
pushback comparison
competitor diagnost
life scienc siemen
competitor diagnost
radiat therapi
jutif
pushback comparison
competitor ultrasound
includ imag modal
mr ct life scienc
siemen
includ point care
competitor ultrasound n/a
ultrasound compound-annual-growth-rate
estim siemen healthin present may
believ advanc therapi busi similar market dynam
imag divis expect siemen continu grow line
pivot question advanc therapi divis grow line
ub view ye believ divis deliv organ growth
evid siemen healthin competitor manag team commentari
market growth expect global intervent imag market
continu grow valu term believ shift toward
minim invas procedur drive volum growth
procedur off-set higher equip util price pressur
market share siemen philip ge domin market
share see similar barrier entri imag
busi littl scope low-cost entrant disrupt market
expect siemen grow line market futur
siemen sale
figur ub estim advanc therapi growth
figur ub estim advanc therapi margin
in-lin market
ub estim market growth
siemen design manufactur wholesal imag robot equip
use therapi minim invas procedur angio-lab cathet
lab intervent radiolog
market growth driver
accord healthin relev market worth grow
year driven
mi util siemen imag robot equip grow
preval due advantag offer versu tradit open surgeri
includ lower risk complic faster recoveri time shorter
hospit stay ultim lower cost expect number mi
procedur number complex procedur grow
medium term
effici expect growth relev procedur believ
growth erod result effici utilis
improv hospit
price estim price pressur year pressur like
focus us view given custom consolid fastest
seen imag space
figur cardio neuro
largest hybrid market
market market via siemen
figur procedur growth expect remain
figur procedur growth translat
use angio-suit hybrid oper room intervent cardiolog
radiolog minim invas procedur system primarili
compos
cathet use replac diseas aortic valv also refer transcathet aortic
valv implant tavi
tabl integr touch screen
surgic c-arm use imag patient undergo surgeri
system provid flexibl tradit imag equip
patient imag sever angl without reposit
surgic tabl c-arm x-ray tube detector attach separ
arm rotat around patient acquir ct-like imag
mobil c-arm smaller cheaper move room
room mobil system typic use extrem procedur hand
ankl wrist knee etc lower power provid
suffici imag qualiti complex cardiolog neurolog procedur
fix c-arm larger system mount either floor ceil
prefer complex procedur provid higher qualiti imag
robot c-arm larger system use robot eas movement
robot c-arm offer flexibl free space
accommod largest heaviest patient siemen first player
develop robot c-arm system part partnership kuka
split modal
tradit ct scanner integr part oper room
integr touch screen record system display ct imag
vital signal procedur
patient tabl integr imag tool use
robot c-arm sensor built system prevent collis
line imag intervent imag market domin
three key player siemen ge philip
figur market domin
see barrier entri imag market limit scope
new low-cost entrant make signific headway industri near
even medium term
technolog radiologist spoken agre
littl technolog product differenti imag manufactur
nevertheless believ technolog hard mimic similar price
healthin spent signific energi develop abil build
reliabl machin cost effici price expertis may hard
brand count even technolog copi brand
purchas price minor portion total cost ownership
opportun cost downtim sometim cite import
consider buy big three purchas manag take
comfort total cost ownership predict
servic requir low-cost competitor offer hardware-onli solut
unlik gain traction provid necessari aftercar
servic requir hospit
access c-suit view siemen strong brand mri ct
ultrasound benefici sale intervent imag equip capital-expenditure
proport time machin broken
budget increasingli decid c-suit level within hospit
offer provid siemen opportun negoti
sale product group
see key differ siemen market peer
consum presenc accord manag siemen
current intend enter consum space instead choos work
partner philip recent enter high-
growth consum market directli via volcano spectranet bolt-on
acquisit philip demonstr abil bundl sale
consum equip believ drive higher growth
healthin presenc
higher-growth consum
ub estim medium-term
base philip commentari volcano acquisit
partnership system healthin partnership
clinic institut medic devic compani revenue-shar model
differ partner
portfolio technolog gap
kuka robot kuka design manufactur robot use part
arti pheno robot c-arm
geting healthin geting cross-sel agreement
place geting suppli oper room compon
surgic light accord manag two sale forc often
pitch busi togeth
healthin equip focus
consum focus cross promot product
differ specialti base channel check healthin seen
specialist cardiolog use procedur surround heart
tavr wherea philip seen specialist within peripher vascular
procedur blood vessel associ heart
philip target organ growth imag guid therapi divis
figur peer growth margin summari tabl
justif
pushback comparison
includ imag life
base imag
spectranet
intervent rather imag
robot focuss within
organ growth ebita adj margin target
report organ growth
angio suit cathlab robot c-arm imag solut therapi
diagnost segment deliv revenu compound-annual-growth-rate sinc
market grow revenu annual profit margin
potenti estim manag hope atellica new
instrument bring turnaround segment fortun hardwar
test menu comparison suggest atellica offer line competitor
see healthin deliv market growth improv margin
pivot question launch atellica enabl healthin stem
market share loss
figur diagnost
ub view ye though see healthin re-tak lost share
time-frame believ atellica correct issu found previou platform
market highli sticki competitor also launch new devic
evid comparison test menu hardwar specif vs mainstream
peer well channel check lab manag
market growth revenu growth continu despit near-term
us uncertainti protect access medicar act pama effect
januari cut medicar reimburs healthin custom
 next three year
market share believ healthin histor under-perform
driven failur previou instrument dimens analysi test
menu hardwar specif suggest atellica launch
resolv key shortcom par competitor product
margin cash flow think bottom end mid-term guid
profit adj margin rang realist given confid atellica
howev believ segment cash flow gener like remain
challeng due atellica placement invest capit
ub estim market growth
busi involv design manufactur wholesal autom
test equip use clinic test laboratori primari focu
high-volum central test lab well smaller hospit lab individu
test use point care
consolid custom
integr test
disciplin atellica
market growth
focus larg refer lab
take share
one domin high-volum
result share loss
exposur fast-grow
disciplin mdx
flow gener weak
particularli earli stage
threat substitut product
altern patholog lab
protect access medicar act
pama could result step chang
us price pressur
could result higher price
competitor also launch new
bargain power supplier
intens industri rivalri
bargain power custom
special reagent provid
rate industri chang among
high-volum provid low
custom increasingli
threat new entrant
sticki market near-term uncertainti
see diagnost market fundament attract offer defens
revenu growth predict revenu stream thank razor
blade bait hook busi model healthin primari focu high-
volum low-valu test suppli larg refer lab take share
smaller lab view although also suppli high-valu test conduct
point care
see near-term risk signific cut reimburs paid us
govern healthin custom januari see littl impact
base-cas scenario
patient visit local hospit blood sampl taken
sampl collect courier servic deliv larg refer
laboratori minut away contract hospit conduct outpati
enabl healthin aptio autom system
pathologist attach barcod test tube instruct aptio run
vitamin-d test pathologist tip test tube along mani other
load bucket aptio sort test tube remov tube cap
move sampl atellica analyz test conduct
result return request physician via email sampl move
cold-storag without human
razor blade busi
model grow revenu
healthin primari focu
ultra-high-volum laboratori
patient inpati test would like conduct hospit
lab would probabl smaller less autom might equip
atellica analyz would less like aptio autom system
pathologist lot load analyz includ understand except
ensur consist result
market growth driven volum growth
total clinic diagnost market worth sale grow
per year estim driven
volum growth enhanc shift
prevent medicin
volum estim test volum growth annual believ
rate growth ahead gener rate healthcar inflat
diagnost test industri still rel young see gener
shift expenditur cur treatment toward prevent diagnost
price healthin estim industri price pressur equival
per year though may overst pressur seen wider market
sinc healthin focus high-volum low-valu test
figur market grow
point care
ub estim sub-seg growth rate note estim refer
entir ivd market
figur apac us largest lab
siemen healthin note refer relev market
healthin
revenu stream highli sticki
razor blade model high switch cost
see market highli sticki laboratori typic stay loyal
main test provid multi-year period owe factor
long contract busi larg structur razor blade
model wherebi machin sold discount retail
return long-term volum test reagent commit contract
typic last five seven year test provid may offer end
contract lab upgrad equip earli increas loyalti
recur revenu form reagent consum servic
account segment sale
roch estim market size biomerieux estim sysmex
lab manag spoke said rare ever consid list price
equip purchas decis machin typic sold
signific discount list price also reagent/servic compon
agreement account far larger proport total cost
figur reagent account
vast major healthin
high switch cost entir process switch provid take
month involv signific extra work lab technician new machin
undergo extens valid process ensur reliabl accuraci
continu outgo machin technician may requir mani day
even week train learn oper new machin
brand trust channel check found pathologist
avers switch unfamiliar provid key concern appear
reagent instabl result test supplier cut qualiti reagent
order save money reduc consist test result may
reason struggl take share recent
healthin client test laboratori divid three main
hospit inpati test lab typic physic locat insid
hospit except normal own control
hospit lab process test request physician work insid
hospit typic provid result within hour
hospit outreach arrang provid test patient taken
outpati set gp primari care provid outpati
specialist provid test respons day work
typic taken help leverag fix cost base hospit inpati
lab believ outreach work increasingli sold/outsourc
independ lab especi us
independ refer lab so-cal
affili hospit system act outsourc test processor
typic larger even highli autom hospit lab
process test lower cost us independ market domin
quest laboratori corpor america
estim healthin oper skew toward larg independ
laboratori signific busi class size lab
clear trend consolid among laboratori particularli us
labcorp quest take share smaller player
market alreadi rel consolid also europ
figur us high-volum lab take share
note poc point care
figur lab space continu
patholog associ sebr
center diseas detect
believ trend toward consolid predominantli driven cost
consider larg lab afford larger effici analys
equip therefor process test lower unit price smaller
local lab therefor make econom sens centralis test fast
turnaround time critic import
healthin expand point-of-car test
test conduct physician point care poc also increasingli
import provid result within minut import
situat healthin posit recent expand
space small acquisit epoc conworx howev poc
still small rel high-volum busi account sale
healthin invest poc
test expand posit
grow market
healthin oper largest technolog sub-seg
keep focu larg refer lab poc test healthin
focus immunoassay clinic chemistri test sinc
highest-volum disciplin set
figur ivd market split technolog
signific focu immunoassay
clinic chemistri
point care
vitro diagnost ivd involv test sampl human fluid certain
diagnost marker vitro outsid set sampl
could includ almost bodili fluid typic taken healthcar
profession prepar analyz lab
sever test method
test compound bind
typic focu detect pathogen hepat test
sampl surfac mix antibodi attach
enzym third step chemic ad chang
presenc enzym
healthin signific posit immunoassay
oppos vivo test would carri insid live bodi
sake simplif conflat elisa immunoassay immunoassay
gener distinct irrelev detail-orient
antigen test antibodi
either via adsorbt non-specif via captur specif antibodi
signal light radiat
test subject present
antibodi
sampl
marker compound
antibodi
sampl attach
wash away
marker unchang
clinic chemistri refer broad rang test singl compound
sampl test frequent organis panel physician
might order seri test one common panel basic metabol
panel test sodium potassium chlorid bicarbon blood
urea nitrogen creatinin glucos
healthin also signific posit clinic chemistri
molecular diagnost mdx test presenc particular dna
strand also use test infecti diseas
hiv mdx test use amplif process thu advantag
immunoassay detect recent contract diseas even
bodi yet built volum antibodi would
requir immunoassay test effect key disadvantag
cost speed deliveri test result
healthin incub develop mdx product offer
ribonucl acid rna evolutionari precursor deoxyribonucl acid dna
use encod genet inform virus well sub-cellular eukaryot bodi
ad bind
dna interest
dna segment interest
mark
repeat mani time amplifi signal
ub note accur polymeras chain reaction common type molecular diagnost test
tissu diagnost stain look tissu sampl detect abnorm
siemen healthin activ plan enter market
custom lab frequent distinct use test technolog
technolog involv quit differ
coagul haemostasi test blood clot effici
might impair
healthin signific abil test coagul effici
patient intern therefor technolog partnership sysmex
market system siemen healthin display sysmex atellica
coag hardwar atellica coag system advertis
customiz integr siemen healthin autom
regard machin effect stand-alone
figur atellica coag link healthin
system offer standard
figur sysmex also advertis
siemen healthin websit
haematolog field link haemostasi measur
proport physiolog blood relat cell common test red
healthin partnership horiba space although machin
market siemen brand advia could find atellica-brand
devic siemen websit
blood glucos monitor healthin plan start provid
patient-administ blood glucos test kit believ ration
sinc market matur signific price pressur
custom differ serv core busi
believ greatest area market uncertainti current revolv around
chang reimburs healthin us custom result
protect access medicar act pama came effect januari
whilst believ like neg impact healthin busi
long term could least partial off-set volum benefit near term
healthin manag relax potenti impact cite
minor temporari effect competitor also yet seen sustain impact
growth trajectori
client price pressur medicar reimburs like fall
per year least three year commerci insur payment rate also
like fall laboratori tri pass price pressur onto
healthin though given long-term natur contract effect
might felt immedi
impact appar date
major impact healthin
custom read-through less
lab consolid believ smaller less effici lab acquir
increas custom consolid
market share gain believ healthin outsiz market share
among larg highli effici lab quest labcorp may
enabl healthin take market volum growth custom
given healthin busi focus us market see debat
figur healthin diagnost sale focus
figur market share territori show us focu
siemen healthin note sale split custom locat
ub estim base healthin data region sale market
client price pressur pama chang lab test price structur
test laboratori typic paid per-test refer
price paid medicar believ privat insur compani
payment set discount
howev pama act mean medicar payment rate defin
median privat insur payment rate believ like creat
signific price cut healthin custom two reason one direct
direct median privat insur payment rate medicar
payment rate howev medicar price reduct limit
per estim reduct reimburs
declin indirect
indirect also expect privat price decreas medicar pay
accord automat formula rel privat price privat price
larg decid rel medicar price lead declin price
default even loop broken privat payer longer price rel
medicar payment rate still strong visibl market
price help contract negoti lab
reimburs per-panel atp basi sinc one test panel may larg
number test
minor privat test reimburs price defin
discount medicar pay test larg proport may defin
test agre upon rate discount medicar
paid time negoti
unlimit thereaft
median averag reduct test reimburs sinc test see
figur vitamin medicar reimburs
figur increas transpar drive price
lab may seek pass price pressur healthin
laboratori may seek pass increas price pressur onto supplier
healthin howev believ price pressur may take
time pass test manufactur contract typic long term
seven year littl scope price re-negoti mid-contract
cite exampl medicar reimburs declin part
due secondari impact us budget sequestr
obviou secondari impact test provid revenu growth margin
period suggest price pressur immedi pass
refer
medicar want align
rate lower commerci
easi lab pass price
cut healthin
figur quest labcorp saw price pressur
figur obviou impact test provid revenu
scienc
howev think pama could sustain subtl longer-
last impact price
larg lab use pama
persuad hospit lab
outsourc oper
pama could increas rate custom consolid
us believ alreadi one concentr laboratori market
global pama could increas consolid level conduct
channel check heard multipl report larg lab provid
increas effort consolid smaller less cost-effici lab wake
howev basi convers lab oper analysi
healthin competitor portfolio believ healthin outsiz
market share among larger lab oper could therefor benefit higher
volum growth scenario
figur larg player high throughput
near term see risk laboratori delay sign new suppli
agreement due uncertainti around pama thu far though impact
appear limit
healthin manag say small neg impact
busi uncertainti emphas impact minor
roch roch saw growth relev divis cite
custom caution ahead pama tough prior-year
comp growth recov
abbott us core lab busi seen limit impact
north american central point diagnost
figur roch seen custom caution ahead
pama saw recoveri
figur abbott also seen limit impact us
healthin custom lobbi pama argu way privat
price data collect inadequ
healthin one largest four provid lab test equip
slip place last decad segment deliv low-
single-digit organ revenu compound-annual-growth-rate market grow
figur healthin diagnost
figur sinc under-perform peer
 siemen sinc bought bayer abbot bought inver aler
believ healthin under-perform larg due failur
previou platform dimens launch mid-lat
hardwar test menu shortcom
problem previou
gener product appear
resolv
hardwar analysi detail technic hardwar comparison publish
cap today suggest dimens chemistri analyz technic
inferior competitor system
test menu detail side-by-sid analysi competitor menu suggest
dimens requir test menu breadth
improv posit healthin launch atellica octob
gener posit new platform analysi atellica hardwar
test menu suggest dimens problem area
healthin believ atellica superior machin sold
competitor enabl re-tak lost market share howev given
sticki natur market believ turnaround slow also
competitor abbott roch process launch
new machin competit landscap chang believ healthin
achiev organ revenu growth line market
competit landscap
chang
figur see return market growth
ub analysi market literatur note accord healthin
atellica launch uniqu test us analysi
current test menu suggest system test
ub estim market growth
beginn guid lab manag care
base channel check diagnost lab manag see four key
factor apart price drive purchas decis
test menu provid need maxim varieti test offer
physician whilst minim number machin lab run offer
core portfolio expect test may suffici case lab
manag prefer purchas addit specialist equip
nich test possibl
reagent stabil believ lab manag brand percept manufactur
driven stabil qualiti reagent one lab manag spoke
said consid purchas key player sinc experienc
fals posit almost year ago due variabl qualiti reagent
throughput lab manag prefer machin high throughput/sq ft
autom lab manag keen limit labour hour requir run
equip cost reason sinc labour repres test
cog lower error rate element autom includ
monitor eas data input
amount time number test system run without requir input
dimens platform core weak
dimens vista launch integr clinic chemistri
immunoassay diagnost devic product live expect
healthin ceo confirm think major reason
healthin lost market share sinc
figur diagnost under-perform sinc dimens launch
manag acknowledg
bayer diagnost dade behr
grow
siemen acquir
believ dimens inferior hardwar test menu breadth
compar peer
hardwar cap today compar technic specif compet test
analyz side side analysi comparison suggest dimens
materi weak particularli clinic chemistri
test menu breadth also compar test menu offer differ
machin found dimens offer inferior peer especi
result healthin previou offer confus view could
unit singl main offer compani offer five immunoassay
clinic chemistri platform channel check suggest none
perceiv lab manag flagship devic
dimens weak may
forc healthin keep older
machin market
fulli integr two disciplin limit test menu
partial integr advia chemistri
partial integr advia centaur
think dimens disappoint expect older
platform advia immulit could retir may
dimens mid-volum launch although high-
volum alreadi launch siemen describ
dimens platform part best offeringto servic laboratori custom
size suggest product still seen potenti commerci success least
intern stage
siemen healthin
atellica close gap peer current offer
believ atellica address dimens core weak close
technolog gap peer
hardwar cap today compar atellica peer product howev
analysi technic specif suggest atellica significantli
higher capac per sq ft per hour competitor product
hardwar specif line superior
test menu breadth side-by-sid comparison test menu suggest
atellica offer par competitor dimens platform
approv core test offer key peer
atellica launch test initi ambit increas
test near medium-term
addit atellica design modular scale give lab manag
signific flexibl react chang throughput requir may
prove advantag competitor offer
atellica appear correct
analysi cap today side-by-sid technic comparison lead
integr clinic chemistri
dimens core issu clinic chemistri side
cap today compar machin base sheet standardis question
machin measur twice immunoassay clinic
number differ assay program
calibr
copyright colleg american pathologist use permiss
classifi question five categori consid key criteria
base convers pathologist categori
capacity/hour/sq ft big machin
capac speed quickli machin process test
autom much human input requir run machin
sampl machin calibr cope abnorm sampl
eas use flexibl easi machin use
machin best particular metric award point shown tick
tabl worst gave neg point shown
cross tabl metric relev machin score zero
denot tabl asterisk direct comparison atellica platform
avail cap today compar use technic
specif market literatur feel comfort give
tri summaris cap
today technic comparison
quantit score raw data score system shown
central issu appear chemistri capac
headlin comparison suggest chemistri modul fell behind capac
speed autom
figur chemistri modul fall behind speed autom
capac speed
sampl machin calibr
eas use flexibl
ub summari product guid http //www captodayonlin com copyright colleg american pathologist use permiss
atellica specif sheet raw data pleas see appendix
modular system absolut number may therefor compar singl system
howev immunoassay modul compar peer
score ahead calibr eas use suspect less import
factor speed autom
figur immunoassay model line peer
capac speed
sampl machin calibr
eas use flexibl
ub summari product guid http //www captodayonlin com copyright colleg american pathologist use permiss
atellica specif sheet raw data pleas see appendix
modular system absolut number may therefor compar singl system
dimens largest atellica smallest machin
dimens immunoassay advertis capac immunoassay per
hour footprint squar feet atellica almost twice advertis
capac smaller footprint
figur dimens larg unlik atellica immunoassay
ub summari product guid http //www captodayonlin com copyright colleg american pathologist use permiss
atellica specif sheet raw data pleas see appendix
modular system absolut number may therefor compar singl system
similar stori visibl chemistri
figur dimens larg unlik atellica chemistri
ub summari product guid http //www captodayonlin com copyright colleg american pathologist use permiss
atellica specif sheet raw data pleas see appendix
modular system absolut number may therefor compar singl system
dimens chemistri system appear slower peer
dimens chemistri system best metric
associ capac speed market literatur posit
atellica found hard compar head-to-head similar metric
figur chemistri system score poorli capac speed
assay program calibr simultan
number open channel defin
number activ channel simultan
number analyt support reagent contain
start time complet na cl-
start time complet na cl- glucos urea creatinin
start time complet albumin ast alt alp
delay order aspir stat test
capac speed
capac line ahead peer
especi per hour per sq foot
basi short assay time key test
ub summari product guid http //www captodayonlin com copyright colleg american pathologist use permiss
atellica specif sheet raw data pleas see appendix
dimens chemistri system also score best autom metric
suggest human interact requir keep product high
figur dimens chemistri score weakli autom well
capabl impair third parti reagent
walkaway time reagent stabil
line ahead peer
ub summari product guid http //www captodayonlin com copyright colleg american pathologist use permiss
atellica specif sheet raw data pleas see appendix
assay program calibr simultan
number open channel defin
number activ channel simultan
number analyt support reagent contain
start time complet na cl-
start time complet na cl- glucos urea creatinin
start time complet albumin ast alt alp
delay order aspir stat test
capac speed
capabl impair third parti reagent
pierc cap primari tube
sampl volum re-run rang high
sampl volum re-run rang low
autocalibr alert
calibr frequenc drug abus
sampl machin calibr
on-sit respons time engin
eas use flexibl
capac line ahead
peer especi per hour per
sq foot basi short assay time
walkaway time reagent stabil
line ahead peer
automat calibr qualiti
notif reagent liquid
ub summari product guid http //www captodayonlin com copyright colleg american pathologist use permiss
atellica specif sheet raw data pleas see appendix
assay program calibr simultan
number analyt support reagent contain
complet hcg test stat time
delay order aspir stat test
capac speed
sampl volum re-run rang high
sampl volum re-run rang low
number calibr requir analyt
sampl machin calibr
on-sit respons time engin
requir dedic water system
suscept carryov third part reagent
eas use flexibl
atellica highest
capacity/hour/ sq foot high-
throughput system higher
roch coba modul
atellica im walkaway time
hour line ahead peer
automat repeat test dilut
origin sampl
calibr qualiti control
mainten autom
ub summari product guid http //www captodayonlin com copyright colleg american pathologist use permiss
atellica specif sheet raw data pleas see appendix
manag believ atellica superior competitor offer
healthin manag believ atellica superior par
competitor offer interpret argument includ
healthin believ atellica
superior competitor offer
scalabl previous order scale oper custom would
buy multipl dimens system would run separ similar
custom use roch coba could simpli purchas addit
modul add exist system given lab manag uncertainti
test volum would develop see key advantag
modular system atellica design allow scale
differ modul singl interfac
flexibl believ atellica advantag competitor modular
system modul combin differ configur l-shape
u-shap competitor offer modular system appear
central argument appear
flexibl
figur modular system linear
figur atellica configur flexibl
capac atellica offer highest capac per hour per squar foot
high-throughput immunoassay system higher coba
doubl capac dimens
magnet sampl transport track new system allow single-vi
control increas transport speed compar tradit
transport track accord compani
multipl instrument combin onto sampl load transport track
singl interfac base discuss lab manag roch seen market
leader modular system
test menu breadth line peer
believ second reason dimens weak
adequ breadth test menu launch atellica believ
issu broadli fix although market leader roch still
broadest portfolio avail singl high-throughput integr platform
figur atellica test menu par peer unlik dimens
atellica test menu
par peer
ub analysi market literatur
note accord healthin atellica launch uniqu test us analysi
current test menu suggest system test
laboratori must access basic test subset nich test
healthin test peer test avail one
singl platform result laboratori either purchas multipl platform
healthin switch purchas competitor
healthin dimens portfolio smaller overal still strong
subcategori may less issu sinc laboratori
focu infecti diseas exampl might care breadth
test menu particular subcategori howev weak healthin
dimens test menu visibl look total number test
also test within subcategori
figur dimens fewer test avail categori peer
healthin portfolio weak
within across categori
drug abuse/toxicolog
ub analysi test portfolio player
note full data within categori found appendix
figur healthin test menu fragment atellica
platform test
avail dimens
dimens immunoassay
test healthin develop
vitamin test avail dimens
modern test
use saliva rather serum
test avail
dimens specialist
test menu atellica appear broadli equival peer across
figur atellica put healthin par peer
drug abuse/toxicolog
ub analysi test portfolio player
note full data within categori found appendix
atellica portfolio
compar peer
chang particularli clear look particular categori exampl
healthin platform four basic infecti diseas test
cytomegaloviru rubella igg igm antigen result lab
want run healthin hardwar expect handl meaning
amount infecti diseas test forc use immulit immunoassay
system test anoth machin test
atellica carri infecti diseas test menu broadli compar
figur atellica infecti diseas menu compar peer unlik
ub analysi test portfolio player
note full comparison healthin dimens atellica test menu versu peer found
believ atellica close gap competitor offer stand
today howev note number competitor includ abbott
roch current launch launch new product believ
could close integr molecular diagnost disciplin
alongsid immunoassay clinic chemistri
healthin need maintain healthi rate innov order grow
line market view
atellica close gap
futur offer
medium-volum lab high- ultra-high-volum lab might
autom system link specialist control unit test modul
roch appear innov leader
roch coba connect molecular diagnost modul use special
connect modul believ level integr
exist immunoassay chemistri core coba offer even
low level integr may advantag larg lab custom
decid main lab equip provid
healthin offer current announc
intent develop
figur healthin suggest hematolog coagul
integr atellica core offer
atellica integr
disciplin workflow
howev given gener industri trend toward integr see like
compani launch solut integr atellica
autom urinalysi atellica mdx onto atellica platform
believ work
healthin believ market leader total lab autom tla
solut system enabl automat movement sampl among
differ area lab
highest level tla would substanti negat benefit fulli
integr multi-disciplin platform sinc process sampl load
result output would requir human input either way howev tla
requir custom design instal lab significantli
expens multi-disciplin integr test platform
financi revenu growth improv
anticip diagnost revenu growth margin cash flow gener
improv market-norm level result atellica launch
revenu growth expect revenu remain histor organ
growth rang late custom take time order instal
atellica expect revenu growth improv
margin expect near-term declin margin due cost
atellica launch follow improv lower end manag
guidanc rang
flow expect cash flow also declin near term due
atellica launch see improv toward end forecast
period howev expect cash gener remain low busi due
continu expans atellica instal base well capitalis
revenu growth margin
improv cash may
figur ub estim diagnost growth
figur ub estim diagnost profit margin
ub estim market growth
revenu growth improv slow initi
believ healthin caught case surpass
peer term technolog launch atellica line
manag expect expect growth margin benefit take least
year fulli realis
one-third relev instal base
atellica
instal base healthin target place atellica system
equival one-third current relev instal base expect
growth back-end-load custom take time assess
machin make long-term commit platform view
growth instal base key determin revenu growth given
razor-razorblad model
test menu avail atellica launch test
intent expand menu near mid-term custom may
delay instal atellica portfolio expand
increas size test menu posit top-lin
profit impact custom run larger proport volum
machin expect impact minor sinc increment test
like low volum
regulatori approv receiv yet atellica
receiv ce fda approv healthin expect
receiv japanes regulatori clearanc approv chines
fda
percept convers custom suggest brand percept
take long time improv space
line revenu growth expect see margin larg line
achiev recent year howev see declin profit
adjust margin due atellica launch cost
figur healthin margin weak
figur flow also disappoint
note believ roch margin declin part due price
headwind blood glucos monitor healthin compet
also due invest signific project
diagnost cash flow weak two main reason identifi
capitalis fy healthin capitalis
amortis total book valu capitalis diagnost
healthin manag indic rate amortis
increas atellica launch believ spend
still remain high overal healthin work bring disciplin
atellica workflow model expens flat segment
capitalis like continu
oper leas healthin provid instrument oper leas
custom net cash outflow like continu atellica
healthin expens sold instrument loss rather place
via oper leas estim segment ebit margin would
fy rather report
figur diagnost profit adj bridg
note profit adj capitalis sever cost provid
healthin ub assum healthin oper leas relat
diagnost capital-expenditure back-calcul healthin disclosur
